Amgen Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Amgen Bundle
Unlock Strategic Clarity
Curious where Amgen’s portfolio really sits—market leader, cash cow, dog, or a risky question mark? This snapshot teases the shifts in market share and growth across biologics and newer pipeline plays, but the full BCG Matrix maps every product into its quadrant with numbers that matter. Buy the complete report for quadrant-level placements, data-backed recommendations, and ready-to-use Word and Excel files that make strategy and capital allocation obvious. Get it now and stop guessing—plan with clarity.
Stars
Repatha (PCSK9 inhibitor)
Repatha leads a growing CV category as guidelines and payers in 2024 push lower LDL targets, driving broader access. PCSK9 inhibitors lower LDL by roughly 50–60% and trials like FOURIER showed ~15% RRR in major CV events, with real‑world data sustaining prescriber confidence. Continued education and access work are needed, but current uptake and outcomes momentum suggest durable dominance; hold market share now to compound benefits.
Tezspire (severe asthma)
Fast traction in the biologics severe asthma segment with broad label covering multiple phenotypes including eosinophil-low patients; NAVIGATOR showed ~56% reduction in annualized exacerbation rate. Differentiation on exacerbation reduction is resonating with pulmonologists. Access and specialty distribution still need muscle, so promotion stays elevated and continued investment is warranted to cement first-call status.
Blincyto (ALL bispecific)
Blincyto (blinatumomab) is surging after compelling survival signals and expansion into earlier lines, including the 2021 FDA MRD-positive approval based on the BLAST trial where 78% achieved MRD negativity. Hospital adoption is rising with growing comfort in administration; its high clinical value supports premium pricing as competitors emerge. Scale medical education and infusion capacity to sustain momentum.
Evenity (osteoporosis)
Evenity is positioned as the anabolic-first play in Amgen’s BCG matrix as anabolic-first strategies gain traction; romosozumab showed a 73% reduction in new vertebral fractures in pivotal data, supporting strong clinical differentiation. Sequencing with Prolia enhances patient retention and outcomes; market education is the main barrier but adoption shows a clear growth curve—keep the field force active to drive category leadership.
- Position: Star (high growth, high potential)
- Clinical edge: 73% reduction in new vertebral fractures
- Strategy: Prolia sequencing = higher stickiness
- Need: ongoing market education; prioritize sales force
Oncology biosimilars (Mvasi, Kanjinti, etc.)
Amgen's oncology biosimilars (Mvasi, Kanjinti) — both FDA-approved in 2019 — hold high-share positions in key hospital-administered oncology molecules with sustained hospital and payer pull-through; category expansion continues as institutions standardize to biosimilars. Price compression is constant, but Amgen's scale and supply reliability matter; keep contracting sharp and service levels high to defend and grow share.
- High-share hospital presence
- FDA approvals: 2019
- Category expanding as institutions standardize
- Maintain tight contracting + high service
PCSK9s, anabolic osteoporosis and MRD therapies surge as biosimilars squeeze margins
Repatha: category growth as 2024 LDL targets tighten; PCSK9s cut LDL 50–60% and FOURIER-class RCTs ~15% RRR in major CV events. Evenity: anabolic leader; romosozumab 73% reduction new vertebral fractures. Blincyto: MRD+ survival traction; BLAST 78% MRD negativity. Biosimilars: high hospital share since 2019; pricing pressure persists.
| Product | 2024 metric | BCG | Key stat |
|---|---|---|---|
| Repatha | Expanding access | Star | LDL −50–60%; ~15% RRR |
| Evenity | Growing adoption | Star | 73% ↓ vertebral fractures |
| Blincyto | Line expansion | Star | 78% MRD− (BLAST) |
| Oncology biosimilars | High hospital share | Star | Approved 2019; margin pressure |
What is included in the product
Detailed Word Document
In-depth review of Amgen's products across BCG quadrants, highlighting Stars, Cash Cows, Question Marks, Dogs, and recommended strategic moves.
Customizable Excel Spreadsheet
One-page Amgen BCG Matrix pinpointing portfolio pain points and guiding resource shifts for faster fixes
Cash Cows
Enbrel (inflammation)
Enbrel, a TNF inhibitor with a 26-year legacy since 1998, remains a large, mature franchise with entrenched rheumatology relationships and stable-to-soft volume in established markets. Margins are excellent for Amgen/Pfizer given limited incremental promo required in this well-known class. Strategy: milk the cash cow while investing in patient retention and adherence programs to preserve unit share against biosimilar pressure.
Prolia/Xgeva (denosumab)
Prolia (6-month dosing) and Xgeva (monthly) benefit from deep physician familiarity, strong real-world evidence (FREEDOM: 68% vertebral fracture reduction) and high margins in osteoporosis and oncology bone protection. Combined denosumab net sales were about $6.1 billion in 2024, generating significant free cash flow despite modest growth. Recurring dosing drives predictable revenue; invest in operations to sustain adherence, distribution and supply reliability.
Otezla (psoriasis/psoriatic arthritis)
Otezla remains a cash cow for Amgen: oral convenience and broad access keep it a go-to versus biologics, supporting steady uptake in psoriasis/psoriatic arthritis. Amgen reported Otezla net sales of $1.1 billion in 2024, reflecting mature demand and predictable scripts that drive reliable cash flow. Promo can be tight and targeted, preserving healthy contribution margins while funding next-wave immunology bets.
Kyprolis (multiple myeloma)
Kyprolis remains a cash cow for Amgen with established efficacy in combination regimens and strong trust among heme-onc prescribers. Market growth has cooled due to newer entrants, yet 2024 global revenue of about $2.0B remains solid. Limited incremental marketing spend is required; prioritize lifecycle optimization and real-world evidence to extend commercial runway.
- Established combos and prescriber trust
- 2024 revenue ~ $2.0B
- Market growth cooled, competitive pressure
- Low incremental spend to sustain position
- Focus on RWE and lifecycle to extend runway
Biosimilar base (Amjevita, others) in steady accounts
Amjevita and other biosimilars deliver steady cash flows from contracted hospital and payer books that ensure reliable throughput and predictable margins.
Category growth remained muted in 2024, but favorable substitution economics and scale-based manufacturing know-how protected margin resilience.
Focus on service continuity and avoid price erosion to preserve long-term profitability.
- Steady throughput from contracted channels
- Muted category growth in 2024
- Favorable substitution economics
- Scale and manufacturing protect margins
- Prioritize service, avoid price wars
High-margin biologics and oral staples — protect retention, RWE & lifecycle to defend cash flow
Amgen cash cows: entrenched franchises with high margins, predictable dosing and stable-to-soft growth; prioritize retention, adherence, RWE and lifecycle tactics to defend share and cash flow. Denosumab, Otezla and Kyprolis drove substantial 2024 FCF while biosimilars and category maturity limit growth; focus on service continuity and targeted promo.
| Product | 2024 net sales | Notes |
|---|---|---|
| Prolia/Xgeva | $6.1B | Denosumab combined |
| Otezla | $1.1B | Mature oral franchise |
| Kyprolis | $2.0B | Heme-onc staple |
| Enbrel/Amjevita | N/A | Steady biosimilar throughput |
What You’re Viewing Is Included
Amgen BCG Matrix
The file you're previewing here is the exact Amgen BCG Matrix report you'll receive after purchase—no watermarks, no placeholders, just the finished, presentation-ready document. It’s built for strategic clarity and immediate use: edit, print, or drop into your deck without fuss. Once purchased, the full file is delivered straight to your inbox—no surprises, no extra steps. Trust the preview: it’s the real thing, made by strategy pros for busy teams.
Dogs
Neulasta (pegfilgrastim)
Neulasta (pegfilgrastim) sits as a declining BCG dog after multi‑entrant biosimilar competition since 2018 sharply eroded share and pricing power, with reported ASP declines in several markets exceeding 50% by 2024. Turnaround investment is unlikely to restore prior margins; Amgen should service residual demand with a lean footprint. Prioritize orderly decline and cash preservation while minimizing capex.
Epogen (epoetin alfa)
Epogen (epoetin alfa), FDA-approved in 1989, sits in a mature, heavily commoditized segment now facing multiple biosimilar entrants and price pressure. Little strategic upside remains and aggressive investment is unlikely to pay back given commoditization and margin compression. Recommend managing down inventory, prioritizing essential contracts and minimizing discretionary spend. Monitor biosimilar uptake and contract renewals closely.
Aranesp (darbepoetin)
Aranesp (darbepoetin) sits in chronic decline in a low-growth, payer-tough market, with 2024 showing continued year-over-year sales erosion as payers favor cost-containment and biosimilars. Competitive and clinical trends, including biosimilar uptake and limited new-label upside, cap growth potential. Best play is disciplined harvesting to maximize remaining cash flow. Free up field resources to redeploy to higher-return assets.
Aimovig (migraine)
Aimovig sits in the Dogs quadrant: the CGRP migraine class is crowded with four approved monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) plus multiple oral gepants by 2024, driving intense promotion and share pressure. Economics are tight and clinical differentiation is marginal, so heavy promotional spend is unlikely to restore growth; prioritize a light commercial footprint and target profitable pockets.
- Position: Dog
- Class: 4 mAbs + gepants (2024)
- Strategy: light touch, focus profitable segments
- Risk: promo-intensive, thin differentiation
Imlygic (oncolytic therapy)
Imlygic (talimogene laherparepvec) is FDA‑approved (2015) oncolytic therapy with niche intratumoral use and operational complexity that limits scale; despite compelling mechanism, commercial traction under Amgen stayed small and it did not move the needle on Amgen oncology revenue by 2024. A big restart would be a sunk-cost decision; maintain minimal support or pursue exit.
- Approval: 2015
- Use: intratumoral, operationally complex
- Commercial: limited traction by 2024
- Action: minimal maintenance or consider divestiture
Harvest aging biologics: prioritize cash, slim footprint, selective divestiture
Dogs: portfolio assets showing structural decline—Neulasta ASP down >50% by 2024 from biosimilar entry; Epogen (FDA 1989) and Aranesp facing commoditization and year‑over‑year sales erosion in 2024; Aimovig in a crowded CGRP market (4 mAbs + gepants by 2024); Imlygic commercial traction remained limited. Prioritize harvesting, lean footprint, selective divestiture.
| Asset | 2024 fact |
|---|---|
| Neulasta | ASP decline >50% (post‑2018 biosimilars) |
| Epogen | Mature, commoditized; legacy product |
| Aranesp | Continued Y/Y sales erosion in 2024 |
| Aimovig | Class: 4 mAbs + gepants (2024) |
| Imlygic | Niche use; limited commercial traction |
Question Marks
Lumakras (KRAS G12C)
Lumakras (KRAS G12C) offers a breakthrough targeted mechanism in a fast-evolving oncology field; FDA approval in 2021 validated the approach but market share remains early given competition. KRAS G12C occurs in ~13% of NSCLC, roughly 200–300k patients globally, defining a sizable but contested addressable market. Regulatory confirmatory trials and combo data will determine the runway—positive signal and combo efficacy can flip this into a Star; if uptake lags, prioritize highest-yield NSCLC indications.
Imdelltra/tarlatamab (DLL3, SCLC)
Imdelltra/tarlatamab gives Amgen a new foothold in DLL3-positive small cell lung cancer, a high-need segment representing roughly 10–15% of lung cancers (~30,000 US cases/year) with DLL3 expressed in ~80–85% of tumors. Early trials reported objective response rates around 23% and median duration of response ~12 months, signaling promising demand. Infrastructure and physician education are critical; invest heavily in centers of excellence and payer access to scale. Winning pivotal phase 3 data and real-world effectiveness will be essential to convert low initial penetration into rapid market share.
Amjevita (adalimumab biosimilar) retail channel
Amjevita retail channel sits in a giant >$20bn US adalimumab retail market (2024) but is fragmented by more than six biosimilars and aggressive rebate competition; share must be earned not assumed. Strategic contracting and patient-support programs will determine uptake and net price realization. Amgen should go big with select payers where unit economics clear, or pull back if net margin per unit fails thresholds.
Olpasiran (Lp(a) siRNA)
Olpasiran, Amgen's Lp(a) siRNA, cut Lp(a) up to 98% in early trials and targets ~20% of adults with elevated Lp(a); today it has zero commercial share but massive cardiovascular upside if outcomes data confirm event reduction. Payer education and scalable Lp(a) diagnostics are required; expect high upfront spend pre-proof. A positive Phase 3 would push it straight into Star territory.
- Early efficacy: up to 98% Lp(a) reduction
- Addressable population: ~20% with elevated Lp(a)
- Current commercial share: 0%
- Key gaps: payer education, diagnostic pathways
- Risk: high pre-proof spend; Phase 3 = Star
MariTide/AMG 133 (obesity)
MariTide/AMG 133 sits in an explosive obesity market projected at about $55 billion in 2024, dominated by Novo Nordisk (~70% share), while Amgen starts from near-zero share. Success hinges on clear differentiation and superior tolerability versus GLP-1 incumbents; heavy R&D and launch spend required. If phase data and manufacturing scale deliver, this can be a franchise-maker; if not, shelve quickly.
- Market 2024 est ~$55B
- Incumbent share ~70%
- High R&D/launch capex
- Outcome binary: franchise vs. shelve
Five late-stage bets face 2024–25 readouts; payor access decides
Amgen's Question Marks (Lumakras, Imdelltra, Amjevita, Olpasiran, MariTide) target large, contested markets with high upside but low current share; outcomes and payor access will determine Star vs. divest. Major binary catalysts in 2024–25: phase 3/readouts, combo data, and pricing/rebate wins. Expect heavy upfront commercial/R&D spend; prioritize indications with clear unit economics and rapid uptake signals.
| Product | 2024 Market/Patients | Current Share | Key Metric | Risk |
|---|---|---|---|---|
| Lumakras | 200–300k NSCLC | Low | KRAS G12C ~13% | Competition |
| Imdelltra | ~30k SCLC | Low | ORR ~23% | Phase 3) |
| Amjevita | $20B adalimumab | Small | Biosimilar pressure | Rebates |
| Olpasiran | ~20% elevated Lp(a) | 0% | Lp(a)↓ up to 98% | Outcomes proof |
| MariTide | $55B obesity | 0% | Need differentiation | GLP-1 incumbents |